Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease

BACKGROUND: Vedolizumab, an α4β7 integrin antagonist, is an effective therapy for Crohn’s disease (CD). Biomarkers are needed to guide therapy and predict outcomes. This study evaluated biomarker concentrations and outcomes in patients with CD undergoing vedolizumab treatment. METHODS: Sera at weeks...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Therap Adv Gastroenterol
Main Authors: Holmer, Ariela K., Battat, Robert, Dulai, Parambir S., Vande Casteele, Niels, Nguyen, Nghia, Jain, Anjali, Miralles, Ara, Neill, Jennifer, Le, Helen, Singh, Siddharth, Rivera-Nieves, Jesus, Sandborn, William J., Boland, Brigid S.
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7675888/
https://ncbi.nlm.nih.gov/pubmed/33240396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284820971214
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados